Loading…
VERU
VERU Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 92536C202
$2.50+2.46%Price as of Sep 22, 22:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $42.63M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.61
- ROE
- -64.54%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -1.16
- 52-week high
- $7.33
- 52-week low
- $2.05
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -96.9% over 5Y.
today you would have $29.78▼ -97.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.14 | $6.50 | $7.20 | $52.80 | $58.90 | $86.50 | $33.50 | $14.00 | $11.40 | $9.10 | $14.50 | $39.20 | $85.00 | $71.80 | $45.10 | $56.90 | $47.30 | |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALGSAligos Therapeutics, Inc. | $6.91 | — | 1.4x | — | -113.59% | $43.15M |
| IXHLIncannex Healthcare Inc. | $3.64 | — | 0.7x | — | -117.17% | $43.55M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |
| MLSSMilestone Scientific Inc | $0.50 |
About the company
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
- 20
- Miami, United States
Company description provided by Yahoo Finance.